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Abstract: 
Cerebral autoregulation is conceptualized as a vascular self-regulatory mechanism within the 
brain. Controlled by elusive relationships between various biophysical processes, it functions to protect 
the brain against potential damages caused by sudden changes in cerebral perfusion pressures and flow. 
Following events such as traumatic brain injuries (TBI), autoregulation may be compromised, potentially 
leading to an unfavorable outcome.  
In spite of its complexity, autoregulation has been able to be quantified non-invasively within 
the neuro-critical care setting with the aid of transcranial Doppler. This information is interpreted 
particularly through calculated derived indices based on commonly-monitored input signals such as 
arterial blood pressure and intracranial pressure (i.e. Pressure reactivity index (PRx), mean flow index 
(Mx), etc.). For example, PRx values that trend towards positive numbers are correlated with 
unfavorable outcome. These predictors are primarily surrogate markers of cerebral hemodynamic 
activity, although suggesting robust correlations between these indices and patient outcome.  
This review of the literature seeks to explain the methodology behind the calculations of various 
measures of autoregulation in adult patients suffering from traumatic brain injuries, and how they can 
interact with one another to both create larger effects on patient outcome and general outcome 
prediction models.  Insight into the driving forces behind cerebral autoregulation is imperative for 
guiding both clinical decision-making and global treatment protocols for neuro-critically ill patients. The 
evidence that autoregulation-oriented therapy may improve outcome after TBI is still oscillating around 
Level III. 
 
Key Words: cerebral autoregulation, traumatic brain injury, pressure reactivity index, intracranial 
pressure, cerebral perfusion pressure, transcranial Doppler, near-infrared spectroscopy 
  
 
Introduction:  
Cerebral autoregulation is the inherent capability of the brain to regulate cerebral blood flow 
across a range of blood pressure within the cranial cavity. During certain pathological conditions, such as 
traumatic brain injury (TBI), it can be depleted. Autoregulation can often be a complicated concept both 
to define and to understand, as it is dependent upon biochemical and physiological interactions that 
have yet to be completely illustrated. Autoregulation has previously been described as a delicate 
balancing act between vasoconstriction and vasodilation as the resistance of the cerebrovascular bed 
adapts1,2 to both sudden and slow dynamic changes in cerebral perfusion pressure (CPP), a product of 
the arterial blood pressure (ABP) and the intracranial pressure (ICP). 
The mechanisms involved in autoregulation are not fully understood.  Various theories have 
been suggested, including: metabolic, endothelial, myogenic, and neurogenic factors leading to the 
regulation of vessel caliber. To date, it is unclear which of these mechanisms predominate in the control 
of cerebral arterial vessel caliber3.  The metabolic theory postulates that byproducts of cerebral 
metabolism lead to alterations in vessel diameter.  However, the changes in extra-cellular metabolic 
byproducts is relatively slow in relation to the rapid response of the cerebral vasculature, thus it may 
not be integral in autoregulatory control3.  Endothelial factors, such as nitric oxide synthase (NOS) and 
endothelin (ET), are expressed as a function of the flow-related stresses encountered by the 
endothelium. It is plausible to consider these endothelial mediators as a potential key player in 
preserved and deranged autoregulatory states3.  Myogenic autoregulatory theories revolve around the 
concept of flow-related stress on the vascular smooth muscle, leading to reflexive changes in vessel 
diameter secondary to varied smooth muscle tone3 Both myogenic and endothelial mechanisms 
probably overlap, forming one reflex, known as autoregulation: CBF remaining independent on changing 
cerebral perfusion pressure.  Finally, the neurogenic hypothesis focuses on neurotransmitter-mediated 
changes in vascular tone, which are believe to stem from fluctuations in sympathetic/parasympathetic 
output to the tunica media3.  One or more of these mechanisms may be the driver(s) of autoregulatory 
control, and are likely subject to derangements depending on the individual host response to injury 
during various neuropathologic conditions3. 
Autoregulation can be disrupted following traumatic intra-cerebral hemorrhages and 
contusions, for example, and is theorized to be a multifactorial event process. Cerebral structural 
integrity can be compromised by injury, leading to the scrambled communication between metabolic 
demand and delivery pathways to the brain via blood vessels, or this can occur in the reverse order.  
However, the appearance of injury severity is not the decisive factor in determining the ability of the 
brain to recover its disposition towards this protective mechanism. Prediction of patient outcome in 
adult TBI is difficult; primarily correlational assessment methods of surrogate markers are relied upon 
for investigation into autoregulation (i.e., pressure reactivity index (PRx), mean flow velocity (Mx), 
oxygen pressure reactivity index (ORx), etc.). One tool that may play a more important role in the 
determination of autoregulatory status in the neurocritical care setting is the application of transcranial 
Doppler (TCD) following traumatic brain injury. TCD can detect irregularities in cerebral blood flow, 
providing diagnostic value for secondary insults like cerebral vasospasm. Residual autoregulatory 
capacity is then described by TCD as “either the speed or the direction of changes” of flow velocity in 
the face of fluctuations in arterial blood pressure4. Figures 1A and IB demonstrate the effects of variable 
ABP and ICP on blood flow velocity in animal models using TCD5-7. 
However, the management of autoregulation has not been standardized in neuro-critical care 
centers, primarily due to lack of “dedicated autoregulation monitors”8. As autoregulation seems to play 
a crucial role in patient treatment and outcome, countering these problems is in the best interest of 
both patients and supervising clinicians. Although forms of continuous monitoring are ideally preferred, 
there are no definitive methods to use or protocols to follow. Despite these limitations, there is a strong 
confirmation from multiple worldwide centers to calculate the pressure reactivity index (PRx) to gauge 
the level of autoregulatory impairment in patients suffering from traumatic brain injuries9. In 
compliance with the most recent Brain Trauma Foundation guidelines10,11, reasserting control of 
cerebral autoregulation is an important goal of the early stages of treatment. The questions of how best 
to quantify measures of autoregulation and additionally, how to interpret this information for directing 
patient management return many, often conflicting, answers. The aim of this brief review is to explore 
some of the more popular derived indices of autoregulatory control mechanisms using TCD within the 
neuro-critical care setting, and to compare how these parameters interact with PRx to influence patient 
outcome after trauma. A comparison of relevant methods of the assessment of autoregulation and their 
respective relationships with outcome are listed in Table 1, with:  PRx, mean flow index (Mx), NIRS-
based spatially-resolved indices and brain tissue oxygenation (PbtO2) -based oxygen reactivity index 
(ORx) highlighted.  Finally, the advantages and disadvantages of each parent monitoring device are 
outlined in Table 2.  
 
 
 
 
 
 
Pressure Reactivity Index (PRx) 
PRx and Patient Outcomes   
PRx, and subsequently, outcome, is affected by interrelationships between such parameters as 
mean arterial pressure (MAP), ICP, and CPP12. These components need to be controlled to drive minimal 
values of PRx, as appropriate vessel diameter modifications spurred by vascular smooth muscle cells 
ensure the protection of the brain 13,14. However, emerging evidence indicates that PRx may be affected 
by many other factors including red blood cell transfusion15, alterations in temperature16, or arterial 
glucose concentration17. 
The PRx is calculated as the moving linear correlation coefficient between MAP and ICP, from 30 
consecutive samples binned into 10-second data windows18. PRx values at or below 0 reflect intact 
autoregulatory reserves. PRx values above 0 indicate the increasing passivity of the cerebrovascular bed, 
in which variations in arterial blood pressure directly influence increases or decreases in ICP. This 
inability of the brain to discriminate the ABP and ICP input, and to mediate vasoconstriction or 
vasodilation accordingly is a predictor of poor outcome. Ideally, in the attempt to preserve cerebral 
autoregulation, these indices should not be co-dependent, as cerebrovascular passivity intimates a 
global autoregulatory disturbance. The utilization of computerized ABP and ICP monitoring to produce 
the PRx as a correlation coefficient has shown to be a robust predictor of outcome following rises in 
intracranial pressure (ICP). Sorrentino et al.19 described critical values of PRx that maximized the 
difference between patients who died (PRx = 0.25) and those with a more favorable outcome (PRx = 
0.05).   
The inherent capacity for this neuroprotective mechanism deteriorates with age20, but is 
especially compounded by TBI18. The age of patients may serve as a predisposition to secondary insults, 
with natural aging processes affecting the reactivity of the cerebrovascular bed20. The impaired state of 
the brain after injury makes it even more vulnerable to and uncompromising with sudden changes in ICP 
and CPP21. For example, large reductions in CPP lead to arteriolar dilations, which in turn decrease 
cerebovascular resistance, and vice versa22. Therefore, the elderly TBI population may be more 
vulnerable to secondary brain injuries caused by reductions in CPP. 
 
Interactions of PRx with Cerebral Metabolic Factors 
In combination with CPP, brain tissue oxygenation (PbtO2) is theorized to act as a surrogate 
marker of cerebral blood flow, taking tissue oxygenation pressure into account23. Disturbances in 
cerebral blood flow after severe head injury directly contribute to the brain’s inability to adjust vessel 
diameter in response to transmural pressure demands. Microdialysis can aid in the detection of TBI-
mediated cerebral metabolic changes. Common markers include glucose, lactate, pyruvate, glutamate, 
glycerol, and the lactate/pyruvate ratio. The relative concentrations of these parameters are associated 
with outcome. For instance, Timofeev et al.24 quantified the lactate/pyruvate ratio as a surrogate marker 
of cerebral metabolism, showing that higher values (>25) reflect an independent association with 
patient mortality attributable to either mitochondrial dysfunction or a lack of oxygen supply in the brain.  
Further assessment of these additional factors’ effects on PRx can be useful in outcome 
prediction.  Steiner et al.25questioned the role of cerebral metabolic dysfunction in suboptimal PRx, and 
subsequently, outcome. The global cerebral metabolic rate of oxygen (CMRO2) was hypothesized to play 
a role in the incidence of dysautoregulation explained by PRx that could prime patients for secondary 
insults to the brain (i.e. ischemia, hyperemia, etc.). Ang et al.26, posited similar oxygen disturbances in 
lesioned tissue as evidence of autoregulatory failure. An inverse relationship between CMRO2 and PRx 
was determined, but the effects of the two could not pinpoint the underlying causes of poor outcome, 
or the dynamics and concentrations of blood in the lesioned part of the brain. Autoregulatory status is 
important for neuro-intensive care management. Autoregulation depends on CPP to balance cerebral 
blood flow and cerebral metabolism25. Elevated CPP can predispose patients to cerebral metabolic 
failure (demonstrated by decreased CMRO2), and thus can potentially drive autoregulatory failure. 
However, there is currently no data available to firmly suggest that changing local metabolics would lead 
to improved autoregulation, although support for the theory that metabolic derangements are 
associated with unfavorable PRx is leant by the work of Timofeev et al.24. It remains to be proven that 
cerebral metabolic alterations will influence patient outcome; for example, CMRO2 signal decreases may 
be a downstream consequence of autoregulatory failure25. 
 
Application of PRx to Optimize Cerebral Perfusion Pressure (CPPOPT) 
The autoregulatory response to CPP changes has been demonstrated within the physiological 
boundaries of 50-100 mmHg, with some studies showing evidence of CPP values above this upper 
bound27,28. Drastic CPP variations after TBI can greatly affect a patient’s chances of survival, and 
additionally, functional outcome1. The progressive failure of autoregulation with falling CPP can predict 
the incidence of secondary, potentially intractable insults to the brain such as delayed cerebral ischemia, 
vasospasm, etc. However, increasing CPP past a “safe” range could lead to hyperperfusion (current 
guidelines stipulate that CPP should rest between 60-70 mm Hg) which has been associated with risk of 
edema or leakages through the blood-brain barrier, as well as potential cardiac or respiratory distress10.  
To simplify cerebral vasoreactivity as a direct measure of pressure and flow, it is perhaps best to 
explain it by its relationship with CPP29.  PRx is the regression between ICP and blood pressure, and CPP 
is the difference between blood pressure and ICP. PRx has been used to derive an optimal CPP (CPPOPT) 
in traumatic brain-injured patients1. CPPOPT is determined from the lowest PRx value plotted against all 
of the CPP values within a recorded period (usually 4 hours). This often results in a simple to 
comprehend U-shaped curve in which CPPOPT is the minimum value found at the base of the curve 
(Figure 2). On the further suggestion of Steiner et al.30 with CPPOPT determined as the lowest-measured 
plotted average of PRx trends, it may be sensible to continually direct patient management towards 0 or 
negative values in accordance with CPPOPT treatment protocols based on pressure autoregulatory 
capacity to protect the patient’s autoregulatory mechanism22,31,32. 
Yet, individualized CPPOPT values may not be contained within the boundaries of 60-70 mm Hg, 
as evidenced by Figure 2, which features a CPPOPT value at 91.14 mm Hg.  Some patients may achieve a 
more stable PRx at CPPOPT above or below the advised “safe” range, an observation which has led 
research to examine the benefits of CPPOPT therapies that are separately tailored to each patient, to 
reduce incidences of secondary injuries across the board4,22,25,33. A recent systematic review conducted 
by Needham et al.1 reaffirms the importance of safeguarding against mortality by treating each patient 
in accordance with his or her individually-determined target CPPOPT to maximize cerebrovascular 
reactivity. 
Criticisms of PRx 
The original definition of PRx functions as a descriptor of “graded loss of autoregulation”30, 
raising the question of whether it is possible to incorporate PRx into CPP management protocols, 
yielding an autoregulatory therapy (perhaps indexed as PRxOPT).  Steiner et al.30 assessed the effect of 
time on PRx and posited that disturbed PRx (reported as PRx >0.2) for a period of six hours was a strong 
predictor of patient mortality. Corresponding CPP values during these observations were analyzed for 
deviations from calculated CPPOPT, however, CPPOPT was unable to be defined in some cases, 
demonstrating that autoregulation-oriented therapy is difficult to implement because it is nearly 
impossible to guarantee the consistency of curve-fitting between surrogate measures of autoregulation.  
CPPOPT fundamentally requires an index of vascular reactivity for its calculation, in addition to high-
frequency data examined every four hours to create time points34. Table 2 at the end of this manuscript 
provides an in-depth description of the strengths and limitations of PRx and other continuous 
autoregulatory indices.  
Aries et al.35 similarly found an obstacle to the design of PRx-guided therapy, stating that the 
fundamental calculation of PRx as a function of arterial blood pressure and intracranial pressure 
assumes that the vacillations of cerebrovascular resistance are coupled with those of cerebral blood 
volume, inducing the direction of ICP towards higher values when intracranial compliance is low, and 
vice versa. The necessity of this pairing is problematic for independent models of PRx-guided therapy 
protocols, as PRx is a “noisy” derived index requiring a higher signal-to-noise ratio and time-domain 
analysis35. To counter this, Aries et al.35 put forth the proposition of PAx (the index of the intracranial 
pressure waveform amplitude) as a modification of PRx that is “potentially independent” of ICP fluxes 
that could affect the validity of PRx as a true measure of autoregulation36.  
Finally, the plot showing the distribution of PRx along various CPP values, contains lot of intrinsic 
calculations. It is PRx: correlation of ABP and ICP, versus difference:  ABP minus ICP. It may be possible 
that the U-shape of this relationship may be derived from the nature of mathematical transformations, 
rather than a physiological relationship. 
 
Mean Blood Flow Velocity Index (Mx) 
The first two days after admission constitute a critical period of autoregulatory equilibration18, 37. 
TCD recordings can judge the ability of these patients to autoregulate despite random fluctuations of 
cerebral perfusion pressure. In this same report by Czosnyka et al38., the Mx was derived from the 
correlation coefficient between mean flow velocity (mFV) within the middle cerebral artery (MCA) and 
cerebral perfusion pressure (an example of this is presented in Figure 3). The MCA is assumed to have a 
constant diameter, although this has yet to be truly validated39,40.  Overall patient outcome 
(dichotomized into “favorable” and “unfavorable” outcome) appeared to be largely affected by positive 
values of Mx within this timeframe, regardless of whether Mx “recovered” to negative values during the 
patient’s course of stay.  
 
 
PRx and Mx have been suggested to describe different components of the autoregulatory 
mechanism and it has been suggested that Mx is a better predictor of functional outcome than of 
mortality,13,41 (PRx is more discriminatory for survival versus mortality); however, both demonstrate U-
shaped curves when plotted against CPP and additionally are directly responsive to alterations of ICP12. 
High values of Mx and PRx insinuate the inability of the cerebral vasculature to regulate cerebral blood 
flow as measured by either of these parameters14. The utility of TCD was further affirmed by Panerai et 
al.42, who compared the quality of the measurement to the sensitivity of gradient-echo magnetic 
resonance imaging (MRI) sequences as a marker of blood flow velocity changes attributable to injury 
and pathology in patients suffering from acute ischemic stroke. However, TCD recordings are generally 
short (< 1 hour), and only able to provide a snapshot of activity within the brain. Additionally, there are 
technical concerns with the device itself, as variable TCD probe placement and non-guaranteed inter-
operator validity cast some doubts on the acceptance of the technique43. The relative strengths and 
limitations of TCD-based assessments are detailed further in Table 2.  
Lang et al. (2003)44 used Mx with TCD to gauge autoregulation in a cohort of TBI patients. 
Recalling that Mx is a continuous measure of slow, spontaneous changes in CPP and cerebral blood flow 
volume (CBFV) applied for the examination of MCA blood flow regularity45, this research group 
attempted to produce the same results with Mx values derived from each of the separate input signals 
of ABP and CPP. Despite revealing a non-significant difference between the discriminatory powers of 
these two input signals, Lang et al. (2003)44 cautioned that Mx as a function of CPP necessitates invasive 
ICP data collection to produce CPP calculations, whereas Mx as a function of ABP does not. As non-
invasive measures of autoregulatory status are prioritized, it seems much more likely for Mx derived 
from ABP as the input to become a routine TCD index than would its counterpart when invasive 
monitoring is undesirable. However, in a more recent study in a larger cohort of patients (n=288), Liu et 
al., 201546 compared Mx derived from both ABP and CPP in outcome prediction, finding CPP to be the 
superior input signal. 
Budohoski et al.47 compared the effects of various components of flow velocity (FV) on 
transcranial Doppler analysis. Citing the calculation of autoregulatory markers as dissociable correlations 
between systolic, diastolic, and mean blood flow parameters, the authors hypothesized that 
autoregulatory information is primarily disseminated by examination of the FV waveform rather than 
the ABP or CPP waveforms. The former may instead serve as “triggers” for autoregulation47. The FV 
waveform was resolved into its constituents systolic (Sx) and diastolic (Dx), and compared with mean 
flow velocity (Mx) in separate analyses using the input signals of ABP and CPP. CPP was determined to 
be the better input signal, with systolic flow indices (Sx) most significantly predicting both outcome and 
mortality (followed by Mx and then Dx), suggesting that relative values of dynamic components of FV 
should be used when assessing autoregulation in TBI patients with TCD47.  
 
Near-Infrared Spectroscopy (NIRS) 
 Near-infrared spectroscopy (NIRS) provides a continuous, dynamic measure of cerebral 
autoregulation through the calculation of the tissue oxygenation index TOx (used interchangeably with 
the cerebral oximetry index, COx), the moving correlation coefficient between invasive ABP and regional 
oxygen saturation (rSO2) over 30 consecutive samples averaged over 10 seconds48. Cerebral oxygenation 
is obtained non-invasively by affixing optodes to a patient’s forehead, which capture the light emitted 
from a single laser diode in the near-infrared spectrum that penetrates the superficial cerebral tissues. 
rSO2 is displayed by NIRS as the tissue oxygenation index, a compilation of the concentrations of 
oxygenated, deoxygenated, and total hemoglobin in region, parameters which can be further 
dissociated by their absorption spectra49,50,51. NIRS has been verified as an alternative technique through 
which to describe autoregulation in TBI patients when ICP monitors are declared unfeasible by the 
nature of pathology. Additionally, NIRS is not operator-dependent like TCD, which makes it more 
accessible to clinicians. However, NIRS can be confounded by factors such as the presence of frontal 
contusions, which can complicate optode placement49.  
TOx is invasive, requiring an arterial catheter for the ABP input signal48. Similar to the acquisition 
of CPPOPT by PRx, recorded ABP values can be plotted against TOx, producing a curve-fitted “ABPOPT” as 
the lowest-associated TOx48,49. Highton et al.50 applied ICP, TCD, and NIRS to compare the agreements 
between PRx, Mx, and TOx in predicting autoregulatory failure. They found that both PRx and Mx were 
significantly correlated with TOx, although there was incomplete agreement between the reactivity 
indices50.  The NIRS-derived total hemoglobin reactivity index (THx), the correlation coefficient between 
the total hemoglobin index (THI =oxygenation + deoxygenated) and ABP, has been suggested as 
analogous to PRx52. THI used in this calculation is described by Diedler et al.52 as “a normalized measure 
of [total] hemoglobin concentration and thereby provides a tracer of cerebral blood volume”. NIRS-
based THx has been suggested as a non-invasive substitute for PRx, supporting the PRx-THx association 
reported by Zweifel et al.49, who posited that ABP can provide a “reasonable approximation” of CPP. 
Later work by Dias et al.53 examined the calculation of CPPOPT with TOx instead of PRx, although the 
results of that single-center study have yet to be confirmed as evidence of the influence of NIRS for 
CPPOPT determination. Further details on the relative strengths and limitations of the application of NIRS 
for autoregulatory assessment are available in Table 2. 
 
Oxygen Reactivity Index (ORx) 
Collating analog MAP, ICP, CPP, and brain tissue oxygen (PbtO2) data from double-lumen skull 
bolts (Licox IM2, Integra NeuroSciences Inc.)  inserted in the right frontal region of the brain, Jaeger et 
al.31 calculated the oxygen pressure reactivity index (ORx) as a moving correlation coefficient between 
CPP and the invasively-quantified PbtO2. They discovered parallels between the scoring of ORx and that 
of PRx to measure whether a patient is capable of autoregulating. (Table 2 compares ORx to PRx as has 
been documented within the existing body literature). Similar to PRx, ORx values range between -1 and 
1, with a positive, passive relationship between PbtO2 and CPP indicating impaired autoregulation. 
Figure 4 describes this relationship. 
 
Conclusion: 
Cerebral autoregulation is not fully elucidated, but it is widely agreed-upon that disturbed 
autoregulation directly influences outcome following TBI. This selective review of the existing body of 
literature confirms that the concept of autoregulation is difficult to model, and even more so to 
mediate. Intricate relationships between blood flow and blood pressure govern calculations of derived 
indices of autoregulation, such as that of PRx and Mx, which are suitable for continuous monitoring.  
Assessments of autoregulation, heavily reliant on non-invasive transcranial Doppler analysis of blood 
flow within the middle cerebral artery, can provide deeper insight into autoregulation available, 
although this notion is challenged by both mechanical and data-driven criticism of TCD monitoring. 
Near-infrared spectroscopy can be considered as promising technology, but is still awaiting strong 
proofs.  Despite the absence of a true marker of autoregulatory capacity, the control of this mechanism 
is a central feature of neuro-critical care management plans, whether treating patients in accordance 
with either ICP- or CPP-oriented protocols.  
 
Key Messages:  
 Cerebral autoregulation regulates cerebral blood flow, and is vulnerable to TBI. 
Residual autoregulatory capacity can be affected by combinations of structural 
and metabolic imbalances, which influence outcome prediction following TBI. 
 Non-invasive determinations of autoregulatory status through the application of 
TCD and NIRS can direct ICP- or individual CPPOPT - based therapies. These 
techniques carry very little risk of patient disturbance or of infection. 
 Cerebral autoregulation cannot yet be directly measured, but can be quantified 
through such surrogate markers as PRx, CPPOPT, Mx, etc. in neuro-critical care 
settings. Favorable outcome, for example, has been associated with low or 
negative values of PRx, Mx, and ORx. 
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Figure Legends: 
 
Figure 1.  Graphs over time highlighting (top to bottom) pressure-passivity of the cerebrovascular bed in 
animal models. Panel A: FVx, ABP, ICP and CPP over a 20-minute recording period in New Zealand white 
rabbits being subjected to intracranial hypertension. There is a robust correlation (R=0.96) between FVx 
and CPP below lower limit of autoregulation6. Panel B: Doppler flow, ABP, ICP, and CPP during a 2-hour 
recording period in piglets with induced arterial hypotension. ICP and ABP are strongly-correlated below 
the lower limit of autoregulation (R=0.70), again demonstrating pressure-passivity with decreasing ABP 
accompanied by decreasing ICP7. [FVx = middle cerebral arterial flow velocity, ABP = arterial blood 
pressure, ICP = intracranial pressure, CPP = cerebral perfusion pressure, mm Hg = millimeters of 
Mercury].  
 
Figure 2. An example of CPP derived from PRx obtained from a single patient over a monitoring period of 
approximately 4 hours. The green, yellow, orange, and red bars of PRx respectively represent a 
spectrum of favorable to unfavorable PRx during the observation. These values of PRx are plotted 
against CPP, with the minimum value of the curve declared CPPOPT.  In this particular patient, CPPOPT is 
equivalent to 91.14 mm Hg. [PRx = pressure reactivity index, CPP = cerebral perfusion pressure, mm Hg = 
millimeters of Mercury].  
 
Figure 3. Dynamic changes in flow velocity and cerebral perfusion pressure as captured during  a 
transcranial Doppler recording for a single TBI patient over 5 minutes. Cerebral autoregulation can be 
approximated by a calculation of Mx from the correlation coefficient between mean FV and CPP, here 
Mx valuie is positive (0.73), denoting disturbed autoregulation). [MCA = middle cerebral artery, FV = 
flow velocity, CPP = cerebral perfusion pressure, Mx = mean flow velocity, mm Hg = millimeters of 
Mercury]. 
 
Figure 4. Panel A: An example of a 50-minute time-trend of ORx derived from PbtO2 plotted against PRx 
obtained from a single patient to demonstrate the similarities in scoring between the indices. Panel B: 
Although this ORx-PRx plot suggests a robust correlation between ORx and PRx (R=0.68), it should be 
noted that PbtO2 can be mechanically altered, whereas ICP is only subject to natural fluctuations within 
the brain – therefore, PRx values cannot change while ABP or ICP remain the same [ORx = oxygen 
pressure reactivity index, PbtO2 = brain tissue oxygenation, PRx = pressure reactivity index, CPP = 
cerebral perfusion pressure, ICP = intracranial pressure, mm Hg = millimeters of Mercury].  
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